Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Tourmaline Bio

Tourmaline CEO Sandeep Kulkarni will take part in a fireside chat today at 1:00 PM ET at the Piper Sandler 35th Annual Virtual Healthcare Conference.

To listen to the webcast, please visit: https://lnkd.in/eGYp3Pb7
 
 #Tourmaline #Immunology #TeamTourmaline #PSCHealthcare2023

Tourmaline CEO Sandeep Kulkarni will take part in a fireside chat today at 3:50 PM ET at the Guggenheim Partners 5th Annual I&I Conference.
 
To listen to the webcast, please visit: https://lnkd.in/eGYp3Pb7
 
 #Tourmaline #Immunology #TeamTourmaline #Guggenheim

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Tourmaline Bio, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jan 29, 2024 11:55 PM	fe4ee50f
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

TRML

COM:TOURMALINEBIO

Tourmaline Bio, Inc.

Last Close

23.50

20/11 21:00

Market Cap

352.13M

Beta: -

Volume Today

154.31K

Avg: -